Twist Bioscience initiated with a Buy at Guggenheim (yesterday)

Guggenheim analyst Subbu Nambi yesterday morning initiated coverage of Twist Bioscience with a Buy rating and $53 price target. The company has a unique DNA synthesis platform that enables a wide range of products with applications in synthetic biology, next-generation sequencing, and even drug discovery, the analyst tells investors in a research note. The firm says Twist’s “considerable growth” in the next-generation sequencing, market appears poised to expand in the coming years. It finds the stock’s risk/reward as “quite compelling.”